{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:39Z","timestamp":1789614159239,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104879","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:19Z","timestamp":1785455779000},"page":"104879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced\/metastatic breast cancer in women aged 70 years and older \u2013 final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study"],"prefix":"10.1016","volume":"89","author":[{"given":"E.","family":"Carola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-6070","authenticated-orcid":false,"given":"P.","family":"Caillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-9927","authenticated-orcid":false,"given":"E.","family":"Paillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-811X","authenticated-orcid":false,"given":"G.","family":"Rochette de Lempdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7643-2956","authenticated-orcid":false,"given":"M.","family":"Bringuier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jovenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boudrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grosjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chakiba-Brugere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Guillem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AC","family":"Hardy Bessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Orfeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-727X","authenticated-orcid":false,"given":"E.","family":"Legouffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Coumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Decrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5011-0290","authenticated-orcid":false,"given":"F.","family":"Bouteiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-9371","authenticated-orcid":false,"given":"E.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104879_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2026.104879_bib2","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2026.104879_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2021.11.011","article-title":"International trends in cancer incidence in middle-aged and older adults in 44 countries","volume":"13","author":"Pilleron","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1634\/theoncologist.10-3-198","article-title":"Never too old? Age should not be a barrier to enrollment in cancer clinical trials","volume":"10","author":"Aapro","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104879_bib5","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/annonc\/mdw259","article-title":"Inclusion of elderly patients in oncology clinical trials","volume":"27","author":"Le Saux","year":"2016","journal-title":"Ann Oncol: official journal of the European Soc Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12916-023-02947-y","article-title":"Eligibility criteria in clinical trials in breast cancer: a cohort study","volume":"21","author":"Szlezinger","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2026.104879_bib8","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline Q and A","volume":"10","author":"Al","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib9","unstructured":"G Curigliano, L Castelo-Branco, A Gennari, N Harbeck, C Criscitiello, D Trapani obotCPGag. ESMO metastatic breast cancer living guidelines, v1.1 May 2023. ESMO Metastatic Breast Cancer Living Guideline2023.."},{"key":"10.1016\/j.breast.2026.104879_bib10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104879_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","article-title":"Palbociclib in older patients with advanced\/metastatic breast cancer: a systematic review","volume":"19","author":"Brain","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.seminoncol.2024.01.003","article-title":"Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer","volume":"51","author":"Sobrini-Morillo","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11912-016-0551-8","article-title":"Age-related disparity: breast cancer in the elderly","volume":"18","author":"Gosain","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.breast.2026.104879_bib15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2147\/CIA.S365497","article-title":"Breast cancer in geriatric patients: current landscape and future prospects","volume":"17","author":"Abdel-Razeq","year":"2022","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.breast.2026.104879_bib16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/cncr.31308","article-title":"Breast cancer-specific survival by age: worse outcomes for the oldest patients","volume":"124","author":"Freedman","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2026.104879_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5152\/ejbh.2020.5659","article-title":"Breast cancer in patients 80 years-old and older","volume":"16","author":"Bertolo","year":"2020","journal-title":"Eur J Breast Health"},{"key":"10.1016\/j.breast.2026.104879_bib18","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","article-title":"Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)","volume":"22","author":"Biganzoli","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib19","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib20","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International society of geriatric oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104879_bib22","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.07.137","article-title":"Multidisciplinary development of the geriatric core dataset for clinical research in older patients with cancer: a French initiative with international survey","volume":"103","author":"Paillaud","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104879_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib25","unstructured":"Observational multicentric national longitudinal study evaluating ibrance (palbociclib) in a real life setting conditions in patients 70 years old and older presenting a locally advanced or metastatic HR+\/HER2- breast cancer (PalomAGE) EU PAS number EUPAS23012. European Medecine Agency, RWD Catalogues.."},{"key":"10.1016\/j.breast.2026.104879_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104879_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.breast.2026.104879_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/bjc.2013.407","article-title":"International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer","volume":"109","author":"Wheelwright","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104879_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib31","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104879_bib32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-024-07524-2","article-title":"Real-world quality-of-life of patients with HR+\/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS","volume":"209","author":"Rocque","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104879_bib33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104879_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-024-07287-w","article-title":"First-line therapy with palbociclib in patients with advanced HR(+)\/HER2(-) breast cancer: the real-life study PALBOSPAIN","volume":"206","author":"Mart\u00ednez-Ja\u00f1ez","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104879_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-RF01-03","article-title":"PARSIFAL-LONG: extended follow-up of hormone receptor-positive\/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study","volume":"84","author":"Llombart-Cussac","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104879_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1237751","article-title":"Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older","volume":"13","author":"Brufsky","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104879_bib37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2147\/CLEP.S373291","article-title":"Oncology drug effectiveness from electronic health record data calibrated against RCT evidence: the PARSIFAL trial emulation","volume":"14","author":"Merola","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.breast.2026.104879_bib38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/j.breast.2026.104879_bib39","first-page":"1039","article-title":"First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+\/HER2- metastatic breast cancer: a real-world cost-effectiveness assessment in a US Medicare-eligible population","volume":"31","author":"Sun","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.breast.2026.104879_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CAD.0000000000000589","article-title":"Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer","volume":"29","author":"Durairaj","year":"2018","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.breast.2026.104879_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104769","article-title":"Real-world effectiveness of CDK4\/6 inhibitors in older patients with HR+\/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study","volume":"87","author":"Ligorio","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104879_bib42","doi-asserted-by":"crossref","unstructured":"Caillet P, Pulido M, Brain E, Falandry C, Desmoulins I, Ghebriou D, et al. PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation. In: Oncol JC, editor. ASCO2021. p. 1012..","DOI":"10.1200\/JCO.2021.39.15_suppl.1012"},{"key":"10.1016\/j.breast.2026.104879_bib43","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.3390\/curroncol31070279","article-title":"Improving care for older adults with cancer in Canada: a call to action","volume":"31","author":"Cook","year":"2024","journal-title":"Curr Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:15Z","timestamp":1789612335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S096097762600189X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104879","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced\/metastatic breast cancer in women aged 70 years and older \u2013 final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104879"}}